Manulife (Manufacturers Life Insurance)
BTAI icon

Manulife (Manufacturers Life Insurance)’s BioXcel Therapeutics BTAI Stock Holding History

Manulife (Manufacturers Life Insurance)’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-603
Closed -$293K – 3125
2021
Q3 		$293K Buy
603
+28
+5% +$12.3K ﹤0.01% 2686
2021
Q2 		$267K Buy
575
+106
+23% +$57.8K ﹤0.01% 2897
2021
Q1 		$324K Sell
469
-26
-5% -$20.9K ﹤0.01% 2568
2020
Q4 		$366K Buy
495
+55
+13% +$42.8K ﹤0.01% 2397
2020
Q3 		$305K Buy
440
+30
+7% +$22.5K ﹤0.01% 2285
2020
Q2 		$333K Buy
+410
New +$267K ﹤0.01% 2180

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Manulife (Manufacturers Life Insurance)'s BTAI Position: Q4 2021 in Review

Manulife (Manufacturers Life Insurance) sold out of BioXcel Therapeutics (BTAI) in Q4 2021, closing a stake of 603 shares — an estimated $293K sold.

Manulife (Manufacturers Life Insurance) first reported a position in BTAI in Q2 2020 and held it in 6 quarters. The position peaked at $366K in Q4 2020. 93 funds tracked by Wall St. Rank hold BTAI as of Q4 2021.

  • Manulife (Manufacturers Life Insurance) reported no remaining BioXcel Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Manulife (Manufacturers Life Insurance) sold 603 BioXcel Therapeutics shares in Q4 2021, an estimated $293K.
  • Manulife (Manufacturers Life Insurance) first reported a position in BioXcel Therapeutics in Q2 2020 and held it in 6 quarters.
  • Manulife (Manufacturers Life Insurance)'s BioXcel Therapeutics position peaked at $366K in Q4 2020.
  • 93 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q4 2021.

Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q4 2021, filed 16 Feb 2022.